The US Food and Drug Administration (FDA) is moving to fast-track review of three psychedelic drugs being developed to treat mental health conditions, including depression, and post-traumatic stress disorder. The move is part of a broader effort by the Trump administration to address the issue of mental health and recovery, arguing that currently available treatments are inadequate. The FDA has awarded priority review vouchers to two companies studying psilocybin for depression and a drug related to MDMA for PTSD. The vouchers do not guarantee approval but aim to shorten the review timeline from months to weeks. The recent moves reflect growing popular support for psychedelics among supporters of the administration, including combat veterans and followers of the Make America Healthy Again movement led by Health Secretary Robert F. Kennedy Jr. The special treatment for psychedelic drugs is likely to renew scrutiny of the FDA's program for speeding up drug reviews, known as the Commissioner's National Priority Voucher program.